Earnings Call · Q3 FY2023·2023-02-10

Q3 23EPS +16.67%·Rev n/aQ2 23EPS -100.00%*·Rev n/aQ1 23EPS -33.33%·Rev n/aQ4 22EPS -50.00%·Rev n/a⚠ consensus missing

Vistagen Therapeutics, Inc. VTGN

Mark Flather — Chief Executive Officer

Shawn Singh — President and Chief Scientific Officer

Jerrold Dotson — Chief Financial Officer

−28.7%1d on move date−27.6% vs SPY3d−30.9%5d−12.7%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VTGN calls or request research access.

More VTGN calls Browse calls Request research access